1/31
Comprehensive vocabulary review of cardiovascular pharmacology, including antihypertensives, heart failure drugs, antiarrhythmics, antianginals, lipid-lowering agents, anticoagulants, and anemia treatments.
Angiotensin-Converting Enzyme (ACE) Inhibitors
A class of antihypertensive drugs typically ending in '-pril' that act in the lungs to prevent the conversion of angiotensin I to angiotensin II, decreasing aldosterone production, lowering blood pressure, increasing serum potassium, and promoting sodium and fluid loss.
Angiotensin II Receptor Blockers (ARBs)
A class of antihypertensive medications typically ending in '-sartan' that selectively bind to angiotensin II receptors in vascular smooth muscle and the adrenal cortex to prevent vasoconstriction and block the release of aldosterone.
Direct Renin Inhibitor
A class represented by aliskiren (Tekturna) that directly inhibits renin, decreasing plasma renin activity and preventing the conversion of angiotensinogen to angiotensin I to manage essential hypertension.
Calcium-Channel Blockers (CCBs)
Medications typically ending in '-ipine' (along with verapamil and diltiazem) that inhibit calcium movement across myocardial and arterial muscle cell membranes, altering action potentials and blocking contraction to reduce blood pressure, cardiac workload, and myocardial oxygen consumption.
Nonselective Beta-Adrenergic Blocking Agents
Medications ending in '-olol' (such as propranolol, nadolol, and timolol) that competitively block beta-adrenergic receptors throughout the sympathetic nervous system, including cardiac beta-receptors, nephron juxtaglomerular cells, and bronchial smooth muscle.
Beta1-Selective Adrenergic Blocking Agents
Cardioselective agents ending in '-olol' (such as atenolol, metoprolol, and esmolol) that preferentially block beta1-receptors in the heart and juxtaglomerular apparatus at therapeutic doses, making them preferred for patients who smoke or have chronic obstructive pulmonary disease.
Vasodilators
Medications such as hydralazine, minoxidil, and nitroprusside that act directly on vascular smooth muscle to produce relaxation, rapid vasodilatation, and blood pressure reduction, primarily reserved for severe or refractory hypertension and emergencies.
Heart Failure (HF)
A condition in which structural and/or functional irregularities in the heart prevent it from effectively pumping sufficient blood throughout the body, resulting in low cardiac output.
Cardiac Glycosides
A drug class represented by digoxin (Lanoxin) that increases intracellular calcium entry during myocardial depolarization, leading to increased force of contraction, increased cardiac output, slowed heart rate, and decreased conduction velocity.
Digoxin Therapeutic Range
The traditional textbook serum concentration cited as 0.5–2.0ng/mL, where levels below 0.5ng/mL may be subtherapeutic and levels above 2.0ng/mL carry heightened risk for toxicity.
Class 0 Antiarrhythmics
A category of antiarrhythmics represented by ivabradine (Coralan, Corlanor) that acts by blocking hyperpolarization-activated cyclic nucleotide-gated (HCN) channels.
Class Ia Antiarrhythmics
Sodium channel blockers such as disopyramide, procainamide, and quinidine that depress phase 0 of the action potential and prolong the overall action potential duration.
Class Ib Antiarrhythmics
Sodium channel blockers such as lidocaine and mexiletine that depress phase 0 somewhat and shorten the duration of the cardiac action potential.
Class Ic Antiarrhythmics
Sodium channel blockers such as flecainide and propafenone that markedly depress phase 0, producing extreme slowing of conduction with little effect on action potential duration.
Class Id Antiarrhythmics
Antiarrhythmic agents represented by ranolazine (Ranexa) that inhibit the late sodium current occurring after the rapid influx of sodium during an action potential.
Class II Antiarrhythmics
Beta-adrenergic blockers, including acebutolol, esmolol, and propranolol, that block sympathetic stimulation in cardiac tissue to manage arrhythmias.
Class III Antiarrhythmics
Potassium channel blockers such as amiodarone, dofetilide, ibutilide, and sotalol that prolong the refractory period and cardiac action potential duration.
Class IV Antiarrhythmics
Calcium-channel blockers represented by diltiazem and verapamil that slow conduction through the atrioventricular (AV) node to control cardiac rhythm.
Stable Angina
Chest discomfort occurring with no underlying permanent damage to the heart muscle, where basic physiological reflexes surrounding the pain restore myocardial blood flow.
Unstable Angina
A form of ischemic heart disease characterized by episodes of myocardial ischemia and chest pain occurring even when the patient is at rest.
Prinzmetal Angina
Angina pectoris caused by spasm of the coronary blood vessels rather than mechanical vessel narrowing alone.
Nitrates
Antianginal agents such as nitroglycerin, isosorbide dinitrate, and isosorbide mononitrate that act directly on smooth muscle to cause relaxation, dilate veins, arteries, and capillaries, and decrease blood pressure to relieve myocardial oxygen demand.
Bile Acid Sequestrants
Lipid-lowering agents including cholestyramine, colestipol, and colesevelam that bind bile acids directly within the intestine to create an unabsorbable complex excreted in feces.
HMG-CoA Reductase Inhibitors
Lipid-lowering medications ending in '-statin' that block 3-hydroxy-3-methylglutaryl-coenzyme A reductase, impeding cholesterol synthesis to lower LDL levels and modestly raise HDL levels.
Antiplatelet Agents
Medications such as aspirin, clopidogrel, and ticagrelor that block receptor sites on platelet membranes to inhibit platelet adhesion and aggregation, preventing formation of the platelet plug.
Anticoagulants
Medications such as heparin, warfarin, dabigatran, and apixaban that interfere with the normal cascade of blood coagulation to prevent thrombus formation and propagation.
Protamine Sulfate
The specific reversal agent and antidote used exclusively to counteract the blood-thinning anticoagulant effects of heparin.
Vitamin K
The clinical antidote and reversal agent administered to counteract the anticoagulant action of warfarin (Coumadin).
Thrombolytic Agents
Medications such as alteplase, reteplase, and tenecteplase that stimulate the conversion of plasminogen to plasmin to actively dissolve preexisting intravascular clots in conditions such as acute ischemic stroke, STEMI, and pulmonary embolism.
Erythropoiesis-Stimulating Agents (ESAs)
Synthetic drugs (such as epoetin alfa and darbepoetin alfa) that act like natural erythropoietin to stimulate red blood cell synthesis in the bone marrow, targeting a maximum hemoglobin of 11g/dL.
Iron Deficiency Anemia Agents
Oral (such as ferrous sulfate and ferrous gluconate) or parenteral (such as iron sucrose and iron dextran) formulations administered to elevate serum iron concentration for hemoglobin synthesis.
Megaloblastic Anemia Agents
Essential replacement agents consisting of folic acid formulations and vitamin B12 compounds (hydroxocobalamin, cyanocobalamin) required for DNA synthesis, red blood cell stroma production, and nervous system myelin maintenance.